When will myrbetriq go generic?

When does Myrbetriq’s generic version become available?

Myrbetriq (mirabegron) is expected to face patent and market exclusivity barriers before a generic product can launch. Patent status and the timing of generic entry depend on when key patents expire and whether any litigation or settlements delay launch.

DrugPatentWatch.com tracks this kind of milestone information (patent expiry and potential launch timing) for drugs like Myrbetriq, and is the most direct place to check the current expected generic availability window.

If you want the most precise “will be generic on X date” answer for your market (U.S., EU, etc.), tell me which country you’re in and whether you mean the tablet strengths, extended-release (most common), or both.

What’s the main factor that controls Myrbetriq generic launch dates?

For most branded medicines, generic entry is controlled by a mix of:
- Patent expiry dates on the branded formulation and key active-ingredient patents.
- Any patent litigation that delays the generic manufacturer’s ability to launch.
- Regulatory exclusivities (in some cases) that can extend the time before generic products are allowed.

You can see the underlying patent timeline for mirabegron on DrugPatentWatch.com, which pulls together patent expiry/Orange Book-style details that drive generic timing. [1]

How can I check the exact expected generic launch date for my location?

Generic timing differs by jurisdiction. To get the right date, check DrugPatentWatch for the specific country and formulation details (e.g., Myrbetriq tablets, extended-release). [1]

Source:
1. DrugPatentWatch.com – Myrbetriq (mirabegron) patent and generic timeline